| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Emission-Computed | 10 | 2004 | 310 | 0.480 |
Why?
|
| Affinity Labels | 1 | 2013 | 28 | 0.470 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 40 | 0.460 |
Why?
|
| Positron Emission Tomography Computed Tomography | 5 | 2023 | 833 | 0.450 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 8 | 2014 | 305 | 0.380 |
Why?
|
| Yttrium Radioisotopes | 2 | 2009 | 178 | 0.370 |
Why?
|
| Lymphoscintigraphy | 2 | 2020 | 35 | 0.360 |
Why?
|
| Molecular Probe Techniques | 1 | 2009 | 46 | 0.340 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 5767 | 0.340 |
Why?
|
| Clinical Medicine | 1 | 2009 | 24 | 0.340 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 591 | 0.330 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 1073 | 0.320 |
Why?
|
| Lymphedema | 2 | 2022 | 239 | 0.300 |
Why?
|
| Exercise Test | 5 | 2015 | 312 | 0.270 |
Why?
|
| Occipital Lobe | 1 | 2004 | 48 | 0.240 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2015 | 71 | 0.230 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2004 | 101 | 0.220 |
Why?
|
| Fluorine Radioisotopes | 8 | 1997 | 133 | 0.220 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2015 | 180 | 0.220 |
Why?
|
| Temporal Lobe | 1 | 2004 | 192 | 0.210 |
Why?
|
| Axilla | 2 | 2022 | 902 | 0.210 |
Why?
|
| Parathyroid Neoplasms | 1 | 2023 | 185 | 0.210 |
Why?
|
| Sentinel Lymph Node | 2 | 2020 | 216 | 0.200 |
Why?
|
| Strontium Radioisotopes | 2 | 2014 | 26 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1162 | 0.190 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2020 | 37 | 0.190 |
Why?
|
| Lymph Nodes | 2 | 2022 | 2967 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 1429 | 0.190 |
Why?
|
| Upper Extremity | 1 | 2020 | 87 | 0.180 |
Why?
|
| Tumor Hypoxia | 1 | 2019 | 24 | 0.180 |
Why?
|
| Electron Transport Complex I | 1 | 2019 | 62 | 0.180 |
Why?
|
| Oxadiazoles | 1 | 2019 | 57 | 0.170 |
Why?
|
| Neurosurgical Procedures | 1 | 2004 | 609 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 3719 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2018 | 100 | 0.160 |
Why?
|
| Electrocardiography | 3 | 2009 | 1145 | 0.150 |
Why?
|
| Deoxyglucose | 6 | 1996 | 115 | 0.150 |
Why?
|
| Coronary Artery Disease | 3 | 2014 | 1011 | 0.150 |
Why?
|
| Lymphatic Vessels | 1 | 2018 | 143 | 0.150 |
Why?
|
| Coronary Angiography | 3 | 2009 | 598 | 0.150 |
Why?
|
| Extremities | 1 | 2018 | 303 | 0.150 |
Why?
|
| Coronary Stenosis | 2 | 2009 | 117 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5159 | 0.140 |
Why?
|
| Radiopharmaceuticals | 5 | 2023 | 1301 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2020 | 1415 | 0.140 |
Why?
|
| Radionuclide Imaging | 5 | 1998 | 660 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 4367 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2020 | 7551 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 9 | 2020 | 1226 | 0.130 |
Why?
|
| Vaccination | 1 | 2022 | 1123 | 0.130 |
Why?
|
| Heart | 3 | 2015 | 1223 | 0.130 |
Why?
|
| Piperidines | 1 | 2019 | 1035 | 0.120 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 4844 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2008 | 764 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 10035 | 0.120 |
Why?
|
| Coronary Circulation | 1 | 2014 | 253 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2013 | 104 | 0.110 |
Why?
|
| X-Rays | 1 | 2013 | 146 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Radiation Dosage | 2 | 2011 | 1014 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 821 | 0.110 |
Why?
|
| Aged | 19 | 2022 | 70117 | 0.100 |
Why?
|
| Bone Neoplasms | 5 | 2014 | 2576 | 0.100 |
Why?
|
| Dopamine | 1 | 2013 | 312 | 0.100 |
Why?
|
| Humans | 40 | 2023 | 261506 | 0.100 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 15694 | 0.100 |
Why?
|
| Male | 26 | 2022 | 123000 | 0.100 |
Why?
|
| Ligands | 2 | 2013 | 995 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1341 | 0.090 |
Why?
|
| Organophosphorus Compounds | 1 | 2009 | 101 | 0.080 |
Why?
|
| Radioimmunotherapy | 1 | 2009 | 119 | 0.080 |
Why?
|
| Chromogranin A | 1 | 2008 | 65 | 0.080 |
Why?
|
| Female | 27 | 2022 | 141928 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 402 | 0.080 |
Why?
|
| Organometallic Compounds | 1 | 2009 | 191 | 0.080 |
Why?
|
| Multimodal Imaging | 2 | 2023 | 550 | 0.080 |
Why?
|
| Receptors, Somatostatin | 1 | 2008 | 85 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2008 | 107 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2005 | 726 | 0.080 |
Why?
|
| Colorimetry | 1 | 2007 | 31 | 0.080 |
Why?
|
| Adult | 20 | 2020 | 77950 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2009 | 592 | 0.070 |
Why?
|
| Middle Aged | 23 | 2022 | 86204 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 6009 | 0.070 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 4971 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 1374 | 0.070 |
Why?
|
| Retrospective Studies | 11 | 2023 | 37905 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 280 | 0.070 |
Why?
|
| Taxoids | 1 | 2009 | 967 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 39 | 0.070 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 4320 | 0.060 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 14889 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2005 | 1616 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2014 | 3005 | 0.060 |
Why?
|
| Pleural Diseases | 1 | 2004 | 57 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2019 | 289 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 435 | 0.060 |
Why?
|
| Fistula | 1 | 2004 | 76 | 0.060 |
Why?
|
| Viruses | 1 | 2005 | 159 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 129 | 0.060 |
Why?
|
| Tamoxifen | 2 | 1997 | 876 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2007 | 665 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2005 | 1944 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 435 | 0.050 |
Why?
|
| Meningeal Neoplasms | 2 | 1996 | 441 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 4892 | 0.050 |
Why?
|
| Stroke Volume | 3 | 2015 | 577 | 0.050 |
Why?
|
| New York | 2 | 2014 | 104 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 371 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 213 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2019 | 2292 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2005 | 1694 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2019 | 50 | 0.040 |
Why?
|
| Indium Radioisotopes | 2 | 1998 | 65 | 0.040 |
Why?
|
| Echocardiography | 2 | 2015 | 1182 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 100 | 0.040 |
Why?
|
| Methionine | 2 | 1996 | 159 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 4298 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 631 | 0.040 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 29902 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2022 | 12873 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 253 | 0.040 |
Why?
|
| Prognosis | 4 | 2022 | 21713 | 0.040 |
Why?
|
| Sarcoma, Experimental | 1 | 1997 | 68 | 0.040 |
Why?
|
| Exercise | 1 | 2005 | 1183 | 0.040 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 8865 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 1997 | 135 | 0.040 |
Why?
|
| Glioblastoma | 2 | 2019 | 1797 | 0.040 |
Why?
|
| Organ Size | 1 | 2018 | 690 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1997 | 169 | 0.040 |
Why?
|
| Ilium | 1 | 1996 | 54 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2002 | 3842 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 15862 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 121 | 0.040 |
Why?
|
| Parietal Lobe | 1 | 1996 | 66 | 0.030 |
Why?
|
| Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2015 | 7 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 1996 | 112 | 0.030 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 109 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2019 | 611 | 0.030 |
Why?
|
| Endometrium | 1 | 2019 | 470 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10331 | 0.030 |
Why?
|
| Vascular Neoplasms | 1 | 1996 | 114 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 754 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 1995 | 120 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 340 | 0.030 |
Why?
|
| Glioma | 1 | 2005 | 1963 | 0.030 |
Why?
|
| Pentetic Acid | 2 | 2008 | 48 | 0.030 |
Why?
|
| Idarubicin | 1 | 1995 | 446 | 0.030 |
Why?
|
| Meningioma | 1 | 1996 | 289 | 0.030 |
Why?
|
| Neoplasm, Residual | 5 | 1996 | 1656 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1998 | 731 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 846 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1996 | 551 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2014 | 262 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 4307 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 2173 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 518 | 0.030 |
Why?
|
| Hypothalamus | 1 | 1994 | 255 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2011 | 91 | 0.020 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 4849 | 0.020 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 342 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2005 | 342 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1994 | 842 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2015 | 6869 | 0.020 |
Why?
|
| Time Factors | 1 | 2004 | 12926 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1996 | 1216 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1996 | 882 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 840 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 14551 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 999 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2009 | 214 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 5542 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3441 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2009 | 177 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 5112 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1994 | 1538 | 0.020 |
Why?
|
| Platelet Count | 1 | 2009 | 490 | 0.020 |
Why?
|
| Constipation | 1 | 2009 | 177 | 0.020 |
Why?
|
| Risk Factors | 4 | 2009 | 17523 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 684 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2009 | 126 | 0.020 |
Why?
|
| Data Display | 1 | 2007 | 49 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 114 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 3022 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 2008 | 11538 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 409 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1165 | 0.020 |
Why?
|
| Sarcoma | 1 | 1996 | 1725 | 0.020 |
Why?
|
| Flucytosine | 1 | 2005 | 30 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 2005 | 70 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 993 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1271 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 1984 | 22 | 0.020 |
Why?
|
| Kidney | 1 | 1994 | 2146 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 835 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2004 | 36 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2005 | 163 | 0.020 |
Why?
|
| Perfusion | 1 | 2005 | 293 | 0.020 |
Why?
|
| Neoplasms | 2 | 2002 | 15193 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2009 | 2316 | 0.010 |
Why?
|
| Carcinoma | 1 | 1995 | 2578 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 186 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2004 | 183 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 3472 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2008 | 600 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 9180 | 0.010 |
Why?
|
| Fatigue | 1 | 2009 | 1239 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 1082 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1399 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1995 | 2979 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 1290 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 21445 | 0.010 |
Why?
|
| Heart Failure | 1 | 1995 | 2516 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1994 | 2326 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 621 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 4938 | 0.010 |
Why?
|
| Pain | 1 | 2009 | 1658 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 1648 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 5437 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2014 | 32848 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 1459 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2002 | 671 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 3536 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 34495 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 3639 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 4917 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1997 | 32 | 0.010 |
Why?
|
| Technetium | 1 | 1997 | 77 | 0.010 |
Why?
|
| Half-Life | 1 | 1998 | 259 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1997 | 224 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2005 | 2358 | 0.010 |
Why?
|
| Femoral Vein | 1 | 1997 | 66 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 211 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 6089 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 59536 | 0.010 |
Why?
|
| Splenectomy | 1 | 1998 | 158 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 6682 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1997 | 181 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2002 | 1529 | 0.010 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1996 | 23 | 0.010 |
Why?
|
| Sigmoid Diseases | 1 | 1996 | 13 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1997 | 210 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 9244 | 0.010 |
Why?
|
| Colonic Diseases | 1 | 1996 | 71 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1997 | 875 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 6915 | 0.010 |
Why?
|
| Postmenopause | 1 | 1997 | 378 | 0.010 |
Why?
|
| Laryngeal Diseases | 1 | 1995 | 49 | 0.010 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1995 | 71 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1998 | 576 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 2037 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 7548 | 0.010 |
Why?
|
| Edema | 1 | 1995 | 267 | 0.010 |
Why?
|
| Ultrasonography, Mammary | 1 | 1996 | 380 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12221 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 793 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 2927 | 0.010 |
Why?
|
| Myocardium | 1 | 1997 | 1313 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 2803 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 5395 | 0.010 |
Why?
|
| Mammography | 1 | 1996 | 1010 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1994 | 1178 | 0.010 |
Why?
|
| Remission Induction | 1 | 1995 | 3569 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1995 | 1299 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1996 | 2086 | 0.010 |
Why?
|
| Rats | 1 | 1997 | 6086 | 0.010 |
Why?
|
| Cisplatin | 1 | 1995 | 2432 | 0.000 |
Why?
|
| Biopsy | 1 | 1995 | 3443 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 4744 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 14289 | 0.000 |
Why?
|
| Mutation | 1 | 2005 | 15179 | 0.000 |
Why?
|
| Adolescent | 2 | 1995 | 31252 | 0.000 |
Why?
|
| Cytokines | 1 | 1994 | 2809 | 0.000 |
Why?
|
| Infant | 1 | 1995 | 13310 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1995 | 7702 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1995 | 16273 | 0.000 |
Why?
|
| Child | 1 | 1995 | 29154 | 0.000 |
Why?
|